FRR Shares (Makes you Realise)

Equity

Home/ Are You A Trader/ Market Info/ Company Profile/ Smart Quotes

COMPANY PROFILE

DR. REDDY'S LABORATORIES LTD.

NSE : DRREDDYBSE : 500124ISIN CODE : INE089A01031Industry : Pharmaceuticals & DrugsHouse : Dr. Reddy's

BSE1293.4543.1 (+3.45 %)

PREV CLOSE (Rs.) 1250.35

OPEN PRICE (Rs.) 1256.10

BID PRICE (QTY) 0.00 (0)

OFFER PRICE (QTY) 0.00 (0)

VOLUME 53081

TODAY'S LOW / HIGH (Rs.)1256.10 1295.00

52 WK LOW / HIGH (Rs.)1025.9 1404.6

NSE1291.3040.7 (+3.25 %)

PREV CLOSE( Rs. ) 1250.60

OPEN PRICE (Rs.) 1257.50

BID PRICE (QTY) 0.00 (0)

OFFER PRICE (QTY) 1291.30 (174)

VOLUME 1643726

TODAY'S LOW / HIGH(Rs.) 1256.80 1295.80

52 WK LOW / HIGH (Rs.)1020 1405.9

More From Company Profile

Smart Quotes

BSE NSE

1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Trade Value (Rs. in Lacs)

680.98

Dividend Yield(%)

0.62

TTM EPS (Rs.)

82.59

P/E Ratio

15.66

Book Value (Rs.)

379.50

Face Value (Rs.)

MCap (Rs. in Mn)

1079522.79

Price/Earning (TTM)

13.56

Price/Sales (TTM)

4.50

Price/Book (MRQ)

3.41

PAT Margin (%)

23.14

ROCE (%)

25.60

Incorporation Year : 24-02 1984

Management Info :

K Satish Reddy - Chairman GV Prasad - Managing Director

Registered Office :

Address : 8-2-337,Road No. 3,Banjara Hills,
Hyderabad,
Telangana-500034

Phone : 040 - 4900 2900

Email : mail@drreddys.com / shares@drreddys.com

Website : www.drreddys.com

Registrars Details :

Bigshare Services Pvt Ltd

306, Right Wing, Amrutha Ville, Opp. Yasodha Hospital,Raj Bhavan Road,Somajiguda,Hyderabad

Listing : BSE, NSE, New York

NEWS

20Aug Dr Reddys Laboratories informs about a
Dr Reddys Laboratories has informed that the Company has allotted 4,160..

20Aug Dr. Reddy’s Laboratories informs about
Pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosur..

11Aug Dr. Reddy's Laboratories gets EIR for
Dr. Reddy's Laboratories has received the Establishment Inspection Repor..

Financials

	QTR Jun 25	ANNUAL 25
Net Profit	29612	53494
Gross Profit	39363	72359
Operating Profit	42353	83852
Net Sales	78095	231154

Rs. in Millions

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Astrazeneca Pharma I (BSE)

9105.75 (0.80%)

M.Cap (Rs. in Cr)22764.38

Glenmark Pharma (BSE)

2116.25 (3.10%)

M.Cap (Rs. in Cr)59720.75

Gland Pharma (BSE)

1919.35 (2.72%)

M.Cap (Rs. in Cr)31622.52

Wockhardt (BSE)

1496.75 (2.54%)

M.Cap (Rs. in Cr)24321.02

Shareholding Pattern

	PROMOTERS	26.64%
	MUTUAL FUNDS/UTI	13.61%
	FI/BANKS/INSURANCE	10.6%
	NON-INSTITUTION	10.26%
	GOVERNMENT	0%
	FII	0%

Mf Holding

Scheme Name

Hold(%)

ICICI Pru Nifty Pha...

9.88

Nippon India Nifty ...

9.87

ICICI Pru Pharma He...

8.92

Aditya Birla SL Nif...

8.10

Axis NIFTY Healthcare ETF

8.10

ICICI Pru Nifty Hea...

8.09

DSP Nifty Healthcare ETF

8.09

Attention Investors

Stock Brokers can accept securities as margin from clients only by way of pledge in the depository system w.e.f. September 1, 2020. Update your mobile number & email Id with your stock broker/depository participant and receive OTP directly from depository on your email id and/or mobile number to create pledge. Check your securities / MF / bonds in the consolidated account statement issued by NSDL/CDSL every month, Issued in the interest of Investors.

Risk Disclosure on Derivatives | Smart ODR | Mandatory Display | KYC Validation Links

BSE / NSE SEBI Registration No. INZ000279232, Depository Participant SEBI Registration No. – IN DP CDSL 132-2015

Mutual funds - ARN No. 81648 , Investment Adviser SEBI Registration No. : INA000008668.

CLOSE X

Risk Disclosures On Derivatives

9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
On an average, loss makers registered net trading loss close to ₹ 50,000.
Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22

DR. REDDY'S LABORATORIES LTD.

Smart Quotes

Attention Investors

Download Client Registration Documents

Download Client Registration Documents (Rights & Obligations, Risk Disclosure Document, Do's & Don't's) in Vernacular Language :

Filing complaints on SCORESEasy & quick

Risk Disclosures On Derivatives